A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD (P306)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03508700 |
|
Recruitment Status :
Completed
First Posted : April 26, 2018
Last Update Posted : October 1, 2019
|
Sponsor:
Tonix Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Tonix Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | September 30, 2019 |
| Actual Study Completion Date : | September 30, 2019 |